Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach
Research output: Contribution to journal › Journal article › Research › peer-review
The role of health-related economy is crucial due to the finite healthcare resources. Intravenous (i.v.) regimes Nordic FLOX and Nordic FLIRI, and the partly oral alternatives XELIRI and XELOX are four commonly used chemotherapies in the first-line treatment of advanced colorectal cancer (CRC) in the Scandinavian countries, all with different costs.
Original language | English |
---|---|
Journal | Acta Odontologica Scandinavica |
Volume | 51 |
Issue number | 7 |
Pages (from-to) | 840-8 |
Number of pages | 9 |
ISSN | 0001-6357 |
DOIs | |
Publication status | Published - Sep 2012 |
Externally published | Yes |
ID: 45707850